These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996 [TBL] [Abstract][Full Text] [Related]
45. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E Oncology; 2018; 95(1):39-42. PubMed ID: 29694955 [TBL] [Abstract][Full Text] [Related]
46. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. Kesari S; Ram Z; CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638 [TBL] [Abstract][Full Text] [Related]
48. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329 [TBL] [Abstract][Full Text] [Related]
49. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Ma DJ; Galanis E; Anderson SK; Schiff D; Kaufmann TJ; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Flynn PJ; Ligon KL; Buckner JC; Sarkaria JN Neuro Oncol; 2015 Sep; 17(9):1261-9. PubMed ID: 25526733 [TBL] [Abstract][Full Text] [Related]
50. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459 [TBL] [Abstract][Full Text] [Related]
51. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. Behm T; Horowski A; Schneider S; Bock HC; Mielke D; Rohde V; Stockhammer F Clin Neurol Neurosurg; 2013 Oct; 115(10):2142-6. PubMed ID: 23993314 [TBL] [Abstract][Full Text] [Related]
52. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas]. Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307 [TBL] [Abstract][Full Text] [Related]
53. Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide : A mono-institutional experience of 215 patients. Julka PK; Sharma DN; Mallick S; Gandhi AK; Joshi N; Rath GK J Cancer Res Ther; 2013; 9(3):381-6. PubMed ID: 24125970 [TBL] [Abstract][Full Text] [Related]
54. [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. Pikó B; Bassam A; Nagy KA; Török E; Vághy R; Vargáné Tamás R; Puskásné Szatmári K Magy Onkol; 2012 Sep; 56(3):166-70. PubMed ID: 23008824 [TBL] [Abstract][Full Text] [Related]
55. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228 [TBL] [Abstract][Full Text] [Related]
56. Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France. Badaoui N; Meyronet D; Cartalat-Carel S; Guyotat J; Jouanneau E; d'Hombres A; Sunyach MP; Jouvet A; Louis-Tisserand G; Archinet A; Frappaz D; Bauchet L; Honnorat J; Ducray F Rev Neurol (Paris); 2014 Mar; 170(3):222-7. PubMed ID: 24582303 [TBL] [Abstract][Full Text] [Related]
57. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Yang QY; Shen D; Sai K; Mu YG; Jiang XB; Zhang XH; Chen ZP Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):232-5. PubMed ID: 21575527 [TBL] [Abstract][Full Text] [Related]
58. Current and Future Drug Treatments for Glioblastomas. Ohba S; Hirose Y Curr Med Chem; 2016; 23(38):4309-4316. PubMed ID: 27758718 [TBL] [Abstract][Full Text] [Related]
59. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157 [TBL] [Abstract][Full Text] [Related]
60. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]